Fixed-duration lenalidomide maintenance therapy matches continuous overall survival in multiple myeloma, reducing adverse events.
Background
Multiple myeloma (MM) remains a virtually incurable plasma cell malignancy, necessitating continuous therapeutic advancements. Current standard-of-care for newly diagnosed MM often involves lenalidomide maintenance therapy administered until disease progression. However, the optimal duration of this maintenance, balancing efficacy against long-term toxicity and patient burden, has been a significant clinical question. This study addresses the critical gap regarding whether a fixed, shorter duration of lenalidomide maintenance can achieve non-inferior outcomes compared to indefinite administration.
Study Design
This phase 3 randomized controlled trial enrolled 516 patients with standard-risk newly diagnosed multiple myeloma who were not undergoing upfront autologous stem-cell transplantation. Following induction with a proteasome inhibitor-lenalidomide combination, patients were randomized to receive either indefinite-duration (continuous) lenalidomide (n=260) or fixed-duration lenalidomide (for 2 years) (n=256). The primary endpoint was overall survival (OS), with the trial powered to detect a 50% increase in median survival over 9 years of follow-up, involving 395 patients and 204 deaths.
Results
At a median follow-up of 86 months, overall survival (OS) did not significantly differ between the two groups. With 80 deaths in each arm, OS at 7 years was 68.6% in the indefinite-duration group and 69.0% in the fixed-duration group (difference, -0.4 percentage points; 95% confidence interval [CI], -9.0 to 8.3; P=0.93). Progression-free survival (PFS) at 7 years was 36.1% in the indefinite-duration group and 29.7% in the fixed-duration group (difference, 6.4 percentage points; 95% CI, -2.6 to 15.4), suggesting a trend towards better PFS with continuous therapy, though not statistically significant. A key finding was the difference in adverse events: > The incidence of nonhematologic events of grade 3 or higher was significantly lower with fixed-duration lenalidomide at 31.5%, compared to 48.2% with indefinite-duration therapy. The 5-year cumulative incidence of second primary cancers (excluding nonmelanoma skin cancer) was 11.2% with indefinite-duration lenalidomide versus 8.3% with fixed-duration therapy.
Key Findings
- Overall survival at 7 years was comparable: 68.6% (continuous) vs 69.0% (fixed-duration, P=0.93).
- Fixed-duration lenalidomide significantly reduced grade 3 or higher nonhematologic adverse events (31.5% vs 48.2%).
- The 5-year cumulative incidence of second primary cancers was lower with fixed-duration therapy (8.3% vs 11.2%).
- Progression-free survival at 7 years showed a trend towards continuous therapy (36.1% vs 29.7%), but was not statistically significant.
Why It Matters
Fixed-duration lenalidomide maintenance offers a viable, less toxic alternative for standard-risk multiple myeloma patients, potentially improving their quality of life without compromising overall survival. This finding challenges the long-standing paradigm of indefinite maintenance, suggesting that a defined 2-year course of lenalidomide could become a new standard for specific patient populations. For clinicians and patients, this means a potential reduction in long-term side effects, including severe nonhematologic adverse events and secondary primary cancers, without sacrificing the primary goal of extending life. This could significantly impact treatment protocols, allowing for more personalized and tolerable long-term management strategies in MM.
multiple-myeloma
lenalidomide
rct
maintenance-therapy
oncology
adverse-events